3062-13-3

Upstream product

• 3062-07-5 N-L-valyl-L-glutamic acid 
• 100-51-6 benzyl alcohol 
• 2768-50-5 dibenzyl L-glutamate 
• 3062-06-4 Benzyloxycarbonyl-L-valyl-L-glutaminsaeure-dibenzylester 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 66866-46-4 C₁₅H₂₇NO₆ 
• 13734-41-3 t-Boc-L-valine 
• 149836-41-9 Boc-Val-Glu(OBzl)-OBzl 

Downstream Products

• 149836-42-0 Boc-Val-Val-Glu(OBzl)-OBzl 
• 1053295-29-6 Val-Val-Glu(OBzl)-OBzl 
• 149857-42-1 Z-Gly-Pro-Arg(NO₂)-Val-Val-Glu(OBzl)-OBzl 
• 149836-43-1 Z(OMe)-Arg(NO₂)-Val-Val-Glu(OBzl)-OBzl 
• 99235-09-3 H-Gly-Pro-Arg-Val-Val-Glu-OH 

Relevant academic research and scientific papers

Amino acids and peptides. XVII. Synthesis of peptides related to N-terminal portion of fibrin alpha-chain and their inhibitory effect on fibrinogen/thrombin clotting.

Various peptides related to N-terminal portion of fibrin alpha-chain were synthesized by the solution method and the solid-phase method, and their inhibitory effect on fibrinogen/thrombin clotting was examined. Extension of peptide chain from N-terminal t

N-acyl peptide, processes for their preparation and pharmaceutical compositions thereof

N-acylpeptides are disclosed of the formula: STR1 wherein R1 is alkanoyloxy or alkenoyloxy; R2 is alkyl or alkenyl; R3 and R4 are each lower alkyl, hydroxy(lower)alkyl, ar(lower)alkyl, esterified carboxy(lower)alkyl, carboxy(lower)alkyl, protected amino(lower)alkyl or amino(lower)alkyl; R5 is hydrogen, hydroxy(lower)alkyl, protected amino(lower)alkyl, amino(lower)alkyl, carboxy(lower)alkyl or esterified carboxy(lower)alkyl; R6 is carboxy, esterified carboxy or sulfo(lower)alkyl; A1, A2 and A3 are each bond or lower alkylene; and m and n are each an integer of 0 or 1; or its pharmaceutically acceptable salt. These compounds have anti-complementary activity and fibrinolytic activity, and are useful as therapeutic agents for immune-complex diseases or autoimmune diseases such as nephritis, rheumatic diseases, systemic lupus erythematosus, etc. and thrombosis such as cerebral apoplexy, coronary insufficiency, pulmonary embolism, etc.